Answers are grounded in this paper and cite their sources.
The main challenges in the treatment of T-cell lymphoblastic lymphoma (T-LBL) in children and adolescents are twofold: to increase survival rates in concert with reduction of acute and long-term toxicities including the rate of secondary malignancies. The need for molecular and prognostic markers in T-LBL is crucial to allow for systematic treatment optimization and may serve as targets for new treatment approaches.
No takes yet. Share an insight, caveat, or question.
Burkhardt et al. (2016) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: